Clinical trials · New York, NY
Refractory Multiple Myeloma clinical trials in New York
We’re tracking 42 recruiting refractory multiple myeloma studies with a site in or near New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06892522RecruitingPhase 1/Phase 2
T cell therapies for multiple myeloma
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
New York, New YorkAges 18 years+ - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
New York, New YorkAges 18 years+ - NCT06215118RecruitingPhase 1
Combination therapy for relapsed or refractory multiple myeloma
This trial tests a new combination of two drugs, elranatamab and iberdomide, for people whose multiple myeloma has returned or stopped responding to previous treatments. The goal is to see if this combination can help control the disease.
New York, New YorkAges 18 years+ - NCT06827860RecruitingPhase 2
Talquetamab shot for elderly with relapsed multiple myeloma
This study tests a new drug called talquetamab, given as a shot under the skin, for older adults with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if it can help control the cancer with fewer side effects.
New York, New YorkAges 70 years+ - NCT04300998Recruiting
CAR-T therapy study for older adults
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
New York, New YorkAges 60 years+ - NCT05372354RecruitingPhase 1/Phase 2
Testing a new multiple myeloma drug with other treatments
This early-phase study tests how safe a new drug (CC-92480) is and how much it stays in the body, when given with other standard or study treatments. It’s for people whose multiple myeloma has come back or did not respond after prior therapy, with the goal of improving disease control.
New York, New YorkAges 18 years+ - NCT04634552RecruitingPhase 2
Talquetamab study for relapsed or refractory multiple myeloma
This trial studies talquetamab, a medicine given to treat multiple myeloma that has come back or did not respond to prior treatment. It may help shrink tumors and improve disease control, depending on how your myeloma measures and your health status.
New York, New YorkAges 18 years+ - NCT05137054RecruitingPhase 1
Linvoseltamab combo for hard-to-treat multiple myeloma
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
New York, New YorkAges 18 years+ - NCT06106945RecruitingPhase 1/Phase 2
AZD0305 alone or with other drugs for multiple myeloma
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
New York, New YorkAges 18 years+ - NCT05093335RecruitingEarly Phase 1
PET scan test for CXCR4 in many relapsed cancers
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
New York, New YorkAges 18 years+ - NCT04973605RecruitingPhase 1/Phase 2
Sonrotoclax with steroid and other drugs for multiple myeloma
This early-phase study tests sonrotoclax (a cancer medicine) in people with multiple myeloma that has come back or not responded to prior treatment. It also studies different combinations with dexamethasone plus other standard medicines, aiming to shrink tumors and improve control of the disease.
New York, New YorkAges 18 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
New York, New YorkAges 18 years+ - NCT05519085RecruitingPhase 3
Test mezigdomide vs pomalidomide with standard drugs for myeloma
This Phase 3 study compares two combination treatments for multiple myeloma that has come back or not gone away (relapsed or refractory). It aims to see whether mezigdomide, along with bortezomib and dexamethasone, works better than pomalidomide with those same medicines.
New York, New YorkAges 18 years+ - NCT05652335RecruitingPhase 1
JNJ-79635322 for hard-to-treat myeloma or amyloidosis
This Phase 1 study tests how safe and how well JNJ-79635322 works in people with multiple myeloma that has come back or is resistant to treatment, or AL amyloidosis that has already been treated. It may help by targeting cancer cells and abnormal proteins driving these diseases.
New York, New YorkAges 18 years+ - NCT06988488RecruitingPhase 1/Phase 2
Study of mezigdomide plus elranatamab for relapsed multiple myeloma
This trial tests a combination of two drugs, mezigdomide (a pill) and elranatamab (an injection), for people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find the best dose and see if the combination is safe and effective.
Hackensack, New JerseyAges 18 years+ - NCT07096778RecruitingPhase 2
Study of Inobrodib, Pomalidomide, and Dexamethasone for Multiple Myeloma
This trial tests a new combination of three drugs—inobrodib, pomalidomide, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if this new drug adds benefit for patients who have tried other therapies.
Hackensack, New JerseyAges 18 years+ - NCT06630806RecruitingPhase 1
Study of an injection for relapsed or refractory myeloma
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
Hackensack, New JerseyAges 18 years+ - NCT05730036RecruitingPhase 3
Linvoseltamab vs standard treatment for relapsed myeloma
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
Stony Brook, New YorkAges 18 years+
Hear when a new Refractory Multiple Myeloma trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Refractory Multiple Myeloma trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting refractory multiple myeloma studies listed above.
- Memorial Sloan Kettering Cancer Center · 6 studies
- Weill Cornell Medicine · 4 studies
- Hackensack University Medical Center · 3 studies
- Mount Sinai Health System · 3 studies
- John Theurer Cancer Center at Hackensack University Medical Center · 2 studies
- Research Site · 2 studies
- Atlantic Health System
- Icahn School of Medicine at Mount Sinai
What taking part in a refractory multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting refractory multiple myeloma studies in New York.
Common questions
- Are there refractory multiple myeloma clinical trials near New York?
- Yes. We're currently tracking 42 recruiting refractory multiple myeloma studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a refractory multiple myeloma study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New refractory multiple myeloma studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.